The April 2026 Department of Justice order, issued under President Trump’s December 2025 executive order, immediately moved FDA-approved marijuana products and state-licensed medical marijuana into Schedule III while launching an expedited DEA administrative hearing on broader rescheduling from Schedule I. That hearing, set to begin June 29, 2026 and conclude by mid-July, will examine full reclassification and could produce a final rule in the Federal Register shortly afterward. These steps follow the 2024 proposed rulemaking and represent the most recent concrete acceleration of the Controlled Substances Act process. Traders are therefore focused on whether the compressed hearing timeline and any subsequent rulemaking will resolve the broader question before key year-end or quarterly deadlines, with procedural outcomes and potential litigation remaining the primary variables.
Polymarket 데이터를 참조하는 실험적 AI 생성 요약입니다. 이것은 거래 조언이 아니며 이 마켓의 정산에 영향을 미치지 않습니다. · 업데이트$778,463 거래량
2026.03.31
July 31
26%
June 30
<1%
December 31
21%
$778,463 거래량
July 31
$14 거래량
26%
June 30
$343,572 거래량
<1%
December 31
$169,995 거래량
21%
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by July 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.The April 2026 Department of Justice order, issued under President Trump’s December 2025 executive order, immediately moved FDA-approved marijuana products and state-licensed medical marijuana into Schedule III while launching an expedited DEA administrative hearing on broader rescheduling from Schedule I. That hearing, set to begin June 29, 2026 and conclude by mid-July, will examine full reclassification and could produce a final rule in the Federal Register shortly afterward. These steps follow the 2024 proposed rulemaking and represent the most recent concrete acceleration of the Controlled Substances Act process. Traders are therefore focused on whether the compressed hearing timeline and any subsequent rulemaking will resolve the broader question before key year-end or quarterly deadlines, with procedural outcomes and potential litigation remaining the primary variables.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
마켓 개설일: Feb 7, 2026, 5:04 PM ET
거래량
$778,463종료일
2026.03.31마켓 개설일
Feb 7, 2026, 5:04 PM ETResolver
0x65070BE91...This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by July 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.The April 2026 Department of Justice order, issued under President Trump’s December 2025 executive order, immediately moved FDA-approved marijuana products and state-licensed medical marijuana into Schedule III while launching an expedited DEA administrative hearing on broader rescheduling from Schedule I. That hearing, set to begin June 29, 2026 and conclude by mid-July, will examine full reclassification and could produce a final rule in the Federal Register shortly afterward. These steps follow the 2024 proposed rulemaking and represent the most recent concrete acceleration of the Controlled Substances Act process. Traders are therefore focused on whether the compressed hearing timeline and any subsequent rulemaking will resolve the broader question before key year-end or quarterly deadlines, with procedural outcomes and potential litigation remaining the primary variables.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
거래량
$778,463종료일
2026.03.31마켓 개설일
Feb 7, 2026, 5:04 PM ETResolver
0x65070BE91...The April 2026 Department of Justice order, issued under President Trump’s December 2025 executive order, immediately moved FDA-approved marijuana products and state-licensed medical marijuana into Schedule III while launching an expedited DEA administrative hearing on broader rescheduling from Schedule I. That hearing, set to begin June 29, 2026 and conclude by mid-July, will examine full reclassification and could produce a final rule in the Federal Register shortly afterward. These steps follow the 2024 proposed rulemaking and represent the most recent concrete acceleration of the Controlled Substances Act process. Traders are therefore focused on whether the compressed hearing timeline and any subsequent rulemaking will resolve the broader question before key year-end or quarterly deadlines, with procedural outcomes and potential litigation remaining the primary variables.
Polymarket 데이터를 참조하는 실험적 AI 생성 요약입니다. 이것은 거래 조언이 아니며 이 마켓의 정산에 영향을 미치지 않습니다. · 업데이트
외부 링크에 주의하세요.
외부 링크에 주의하세요.
자주 묻는 질문